Sunday 18 October 2026
Export PRLD’s income statement to Excel — free account
Prelude Therapeutics Incorporated
PRLD Healthcare Biotechnology
Prelude Therapeutics Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $12.1 million, up 73.4% from fiscal 2024. In the quarter to June 2026, revenue grew 42.6%, EPS grew 65.9% and free cash flow grew 40.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.26
0.06
−1.81%
Follow PRLD
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | — | — | — | — | — | — | — |
Altman Z-Score |
(6.83) | (5.17) | — | — | — | — | — | — | — |
P/S ratio |
11.66 | 0.00 | — | — | — | — | — | — | — |
P/FCF ratio |
0.00 | 0.00 | — | — | — | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
(17.29) | (8.93) | — | — | — | — | — | — | — |
P/Operating CF |
9.65 | (4.68) | — | — | — | — | — | — | — |
P/B ratio |
3.25 | 0.74 | — | — | — | — | — | — | — |
Price to Tangible BV |
3.25 | 0.74 | — | — | — | — | — | — | — |
EV/Sales |
6.27 | 0.00 | — | — | — | — | — | — | — |
EV/EBITDA |
0.00 | 0.26 | — | — | — | — | — | — | — |
EV/Operating CF |
(2.13) | 0.36 | — | — | — | — | — | — | — |
EV/FCF |
(2.13) | 0.35 | — | — | — | — | — | — | — |
Quick Ratio |
1.95 | 5.21 | 10.67 | 9.30 | 15.17 | 19.19 | 3.90 | 6.37 | — |
Current Ratio |
1.99 | 5.30 | 10.79 | 9.42 | 15.37 | 19.41 | 4.18 | 6.37 | — |
Net Debt/EBITDA |
1.00 | 0.94 | 1.73 | 1.69 | 2.61 | 3.75 | 0.68 | 1.05 | — |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Asset Turnover |
0.08 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.57 | 0.81 | 0.88 | 0.73 | 0.75 | 0.81 | 0.93 | 0.88 | — |
Capex/Depreciation |
(0.05) | 0.27 | 1.52 | (0.77) | (1.02) | (1.15) | (2.04) | 0.00 | — |
| (99.45%) | (69.01%) | (56.33%) | (47.97%) | (44.85%) | (69.95%) | 76.47% | 40.72% | — | |
| (62.81%) | (56.12%) | (48.91%) | (43.93%) | (42.25%) | (46.39%) | (144.06%) | (178.96%) | — | |
ROIC |
0.00% | 0.00% | (1,989.73%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Return on Tangible Assets |
(172.11%) | (108.68%) | (55.11%) | (61.54%) | (39.91%) | (26.86%) | (161.83%) | (105.17%) | — |
Average Days of Receivables |
0.00 | 0.00 | — | — | — | — | — | — | — |
Research and Development Expense of Revenue |
776.77% | 1,685.64% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
184.56% | 410.27% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
98.13% | 304.93% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | — |
Graham Net Nets |
0.15 | 0.95 | — | — | — | — | — | — | — |
Graham Number |
0.00 | 0.00 | — | — | — | — | — | — | — |
Earnings Yield |
(44.48%) | (132.03%) | — | — | — | — | — | — | — |
Free Cash Flow Yield |
(25.26%) | (106.82%) | — | — | — | — | — | — | — |
Revenue per Share |
0.16 | 0.09 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
(0.73) | (1.36) | (1.77) | (1.77) | (1.81) | (3.70) | (15.38) | (0.30) | — |
Capex per Share |
0.00 | (0.01) | (0.06) | (0.06) | (0.05) | (0.05) | (0.47) | 0.00 | — |
Free Cash Flow per Share |
(0.73) | (1.37) | (1.83) | (1.83) | (1.86) | (3.75) | (15.84) | (0.30) | — |
Cash per Share |
1.34 | 1.76 | 3.86 | 4.26 | 6.32 | 17.50 | 11.31 | 0.36 | — |
Shareholders Equity per Share |
0.89 | 1.73 | 3.93 | 4.13 | 6.21 | 17.00 | 10.20 | 0.32 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
0.89 | 1.73 | 3.93 | 4.13 | 6.21 | 17.00 | 10.20 | 0.32 | — |
Free Cash Flow |
(56.37) | (103.65) | (110.58) | (86.75) | (85.85) | (46.80) | (26.44) | (12.95) | — |
Working Capital |
52.70 | 110.25 | 213.76 | 182.68 | 275.91 | 209.43 | 15.39 | 13.15 | — |
Capital Expenditures |
(0.07) | (0.76) | (3.51) | (3.02) | (2.32) | (0.62) | (0.78) | (0.53) | — |
Net Current Asset Value |
33.01 | 91.84 | 195.01 | 179.32 | 275.91 | 209.40 | 15.38 | 13.09 | — |
EV/EBIT |
0.00 | 0.26 | — | — | — | — | — | — | — |
Capex to Sales |
0.01 | 0.11 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Price to Operating Income |
0.00 | 0.00 | — | — | — | — | — | — | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
0.26 | (0.42) | (0.31) | 0.80 | 0.58 | 0.22 | 0.23 | 0.18 | — |
Cash ROIC |
(32.80%) | (39.10%) | (23.53%) | (21.84%) | (14.88%) | (10.87%) | (73.64%) | (43.92%) | — |
Accounts Receivable Turnover |
0.00 | 0.00 | — | — | — | — | — | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.09 | — |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3,336.44 | — |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Payables |
5.86 | 6.16 | 5.68 | 7.31 | 5.88 | 2.95 | 1.67 | 1.67 | — |
Average Assets |
158.42 | 226.59 | 249.08 | 262.80 | 264.34 | 122.73 | 19.14 | 8.20 | — |
Average Common Equity |
100.05 | 184.27 | 216.26 | 240.67 | 249.04 | 81.39 | (36.05) | (36.05) | — |
Columns are period end dates